S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in

Pro-Dex Stock Forecast, Price & News

-1.50 (-5.82 %)
(As of 03/3/2021 12:00 AM ET)
Today's Range
Now: $24.26
50-Day Range
MA: $28.50
52-Week Range
Now: $24.26
Volume25,820 shs
Average Volume33,996 shs
Market Capitalization$93.67 million
P/E Ratio26.97
Dividend YieldN/A
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.


Pro-Dex Announces $25M Offering
January 1, 2021 |  benzinga.com
Is Pro-Dex (NASDAQ:PDEX) A Risky Investment?
December 28, 2020 |  finance.yahoo.com
These Trends Paint A Bright Future For Pro-Dex (NASDAQ:PDEX)
November 30, 2020 |  finance.yahoo.com
Here is What Hedge Funds Think About Pro-Dex, Inc. (PDEX)
November 27, 2020 |  finance.yahoo.com
Pro-Dex, Inc. Announces Fiscal 2021 First Quarter Results
November 5, 2020 |  finance.yahoo.com
When Should You Buy Pro-Dex, Inc. (NASDAQ:PDEX)?
October 23, 2020 |  finance.yahoo.com
Pro-Dex Inc.
September 16, 2020 |  marketwatch.com
Getting In Cheap On Pro-Dex, Inc. (NASDAQ:PDEX) Is Unlikely
September 8, 2020 |  finance.yahoo.com
Stocks With Rising Relative Strength: Zynex
September 4, 2020 |  finance.yahoo.com
Globus Medical Getting Closer To Key Technical Measure
September 4, 2020 |  finance.yahoo.com
Pro-Dex EPS beats by $0.46, beats on revenue
August 27, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:PDEX
Year FoundedN/A



Sales & Book Value

Annual Sales$34.83 million
Cash Flow$1.43 per share
Book Value$4.92 per share


Net Income$6.11 million


Market Cap$93.67 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.86 out of 5 stars

Medical Sector

1105th out of 1,968 stocks

Surgical & Medical Instruments Industry

103rd out of 169 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
-1.50 (-5.82 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PDEX News and Ratings via Email

Sign-up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions

What stocks does MarketBeat like better than Pro-Dex?

Wall Street analysts have given Pro-Dex a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pro-Dex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pro-Dex?

Pro-Dex saw a increase in short interest in January. As of January 29th, there was short interest totaling 21,800 shares, an increase of 91.2% from the January 14th total of 11,400 shares. Based on an average daily volume of 41,900 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.8% of the shares of the company are short sold.
View Pro-Dex's Short Interest

When is Pro-Dex's next earnings date?

Pro-Dex is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Pro-Dex

How were Pro-Dex's earnings last quarter?

Pro-Dex, Inc. (NASDAQ:PDEX) posted its quarterly earnings data on Thursday, February, 4th. The medical instruments supplier reported $0.08 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.35 by $0.27. Pro-Dex had a net margin of 17.34% and a trailing twelve-month return on equity of 33.84%.
View Pro-Dex's earnings history

How has Pro-Dex's stock price been impacted by COVID-19?

Pro-Dex's stock was trading at $18.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PDEX shares have increased by 33.0% and is now trading at $24.26.
View which stocks have been most impacted by COVID-19

Who are Pro-Dex's key executives?

Pro-Dex's management team includes the following people:
  • Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 60, Pay $621.64k)
  • Ms. Alisha K. Charlton, CFO & Corp. Sec. (Age 51, Pay $248.95k)

What is Michael J. Berthelot's approval rating as Pro-Dex's CEO?

3 employees have rated Pro-Dex CEO Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among Pro-Dex's employees.

Who are some of Pro-Dex's key competitors?

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology Group (MRVL) and UnitedHealth Group (UNH).

What is Pro-Dex's stock symbol?

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

Who are Pro-Dex's major shareholders?

Pro-Dex's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.53%), Dimensional Fund Advisors LP (1.36%), THB Asset Management (1.34%), Northern Trust Corp (0.77%), Punch & Associates Investment Management Inc. (0.52%) and Denali Advisors LLC (0.05%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III.
View institutional ownership trends for Pro-Dex

Which major investors are selling Pro-Dex stock?

PDEX stock was sold by a variety of institutional investors in the last quarter, including THB Asset Management, Northern Trust Corp, Punch & Associates Investment Management Inc., and BlackRock Inc.. Company insiders that have sold Pro-Dex company stock in the last year include Alisha Charlton, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot, and William James Farrell III.
View insider buying and selling activity for Pro-Dex
or view top insider-selling stocks.

Which major investors are buying Pro-Dex stock?

PDEX stock was bought by a variety of institutional investors in the last quarter, including Denali Advisors LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Pro-Dex
or or view top insider-buying stocks.

How do I buy shares of Pro-Dex?

Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pro-Dex's stock price today?

One share of PDEX stock can currently be purchased for approximately $24.26.

How much money does Pro-Dex make?

Pro-Dex has a market capitalization of $93.67 million and generates $34.83 million in revenue each year.

How many employees does Pro-Dex have?

Pro-Dex employs 117 workers across the globe.

What is Pro-Dex's official website?

The official website for Pro-Dex is www.pro-dex.com.

Where are Pro-Dex's headquarters?

Pro-Dex is headquartered at 2361 MCGAW AVENUE, IRVINE CA, 92614.

How can I contact Pro-Dex?

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]

This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.